Are there newer Erythropoiesis Stimulating Agents (ESAs)?
Methoxy-pegylated epoetin beta (Mircera) was approved by the FDA in 2008, but its introduction into the U.S. market was delayed until 2015 because of patent infringement issues.
Methoxy-pegylated epoetin beta is effective when administered once monthly and has the same FDA recommendations regarding dosing and target Hb levels as epoetin and darbepoetin.
Its long duration of action may make it attractive to non-hemodialysis patients who require subcutaneous ESA administration.